Why Tolerability Will Drive The Next Wave Of Obesity Treatments
By HH Kim, CEO, MetaVia
The obesity treatment landscape is changing rapidly. With the rise of GLP-1 receptor agonists and combination therapies, pharmaceutical innovation has primarily focused on maximizing effectiveness, leading to greater weight loss and better metabolic outcomes. However, as the market matures, a different factor is becoming just as important: tolerability.
For the next generation of obesity medicines, enhancing how patients experience therapy, such as how quickly they can reach effective doses, how well they can stay on treatment, and how smoothly therapies integrate into real-world care, will inform discovery and development efforts and may ultimately determine long-term success.
From Efficacy To Experience
First-generation GLP-1–based therapies have revolutionized obesity treatment, but they include some trade-offs. Many require complex titration schedules, often involving multiple dose increases over several months to reduce gastrointestinal (GI) side effects.
This causes challenges throughout the treatment process for patients. They may face nausea or discomfort during dose escalation. Titration schedules need to be managed carefully. Some current therapies can require up to five titration steps over six months just to reach a therapeutic starting point. Additionally, patients often pay the price of months of suboptimal dosing before reaching full effectiveness.
In some cases, patients discontinue therapy before ever reaching the optimal dose or their weight loss goals. So why is there a tolerability gap?
The Tolerability Gap
Despite the strong effectiveness of current obesity medications, a significant portion of patients struggle with tolerability. Some patients cannot handle gastrointestinal side effects at all, while others develop tolerance over time, reducing the medication's effectiveness. In type 2 diabetes, closely associated with obesity, this challenge is even more significant. Although GLP-1 therapies are commonly used, an estimated 20% or more of patients might not tolerate them or respond sufficiently, often resulting in a need to escalate to insulin.
Given the tolerability hurdle, this information can help inform preclinical research and early-stage drug development by enabling researchers to identify more tolerable treatment options that are more likely to respond well and succeed once they advance into clinical trials. Researchers are starting to lean into more combination approaches to address this challenge head on.
Why Tolerability Is Becoming The Key Differentiator
As the obesity market becomes increasingly crowded, with GLP-1s, dual agonists, and triple combinations, the industry is shifting toward a new reality: no single drug will do everything. Future success will depend on differentiation. And increasingly, that differentiation may come from simpler dosing regimens, reduced need for titration, improved side effect profiles, and faster time to therapeutic benefit.
Tolerability and titration are deeply linked. A highly tolerable drug enables fewer dose-escalation steps or potentially none at all. If a therapy can reduce titration to one or two steps, or eliminate it entirely, it changes everything. You could achieve effective dosing in weeks rather than months. That’s a game changer.
Rethinking Titration: A Path Forward
Emerging candidates are beginning to challenge the status quo. Some investigational therapies are exploring non-titrated dosing approaches, higher initial doses with acceptable safety profiles, and faster escalation timelines. Early clinical data suggest that it may be possible to achieve meaningful weight loss with minimal or no titration, while maintaining tolerability. This could have significant implications, leading to faster patient outcomes, lower overall treatment costs, and improved adherence and persistence.
Combination Approach
As the GLP-1 market continues to develop, companies are moving beyond simple monotherapy to explore combination strategies that tackle ongoing tolerability issues and enhance long-term results. Although GLP-1 treatments have revolutionized weight management, side effects like nausea, vomiting, and gastrointestinal discomfort, combined with inconsistent patient responses, still restrict their potential. This has led the industry to adopt more advanced methods, pairing GLP-1 with other metabolic mechanisms to achieve better outcomes.
A key area of innovation in R&D efforts is the development of GLP-1/glucagon dual agonists. Although this approach may seem new in today’s market, it has been researched since the mid-2010s. Early clinical trials, including those progressing to Phase 2 for type 2 diabetes, did not meet their endpoints, but they provided vital insights for current development. The most important lesson is the need to find the right balance between GLP-1 and glucagon activity. Mechanistically, this relationship is delicate: GLP-1 reduces glucose levels, whereas glucagon increases them. Excess of either can compromise the therapeutic goal.
Currently, the industry is experimenting with various GLP-1 to glucagon ratios to find the optimal balance. Some initiatives, like Altimmune's work with pemvidutide, have tested a 1:1 ratio, but this has shown limited effectiveness in glucose regulation. Others prefer a higher GLP-1 proportion, such as 6:1 or 8:1, though these ratios haven't consistently produced significant metabolic improvements in clinical trials. Increasing evidence indicates that using more GLP-1 alone isn't the solution; instead, better results will come from carefully tuning the interaction between these pathways.
Overall, these developments indicate a wider change in the industry’s approach to obesity and metabolic disease. They are now viewed not as conditions that can be solved by a single mechanism but as complex chronic diseases that need nuanced, multitargeted, and patient-focused strategies.
The Road Ahead
By 2030, the obesity treatment market is expected to become much more crowded, competitive, and technologically advanced. Many therapies will show strong effectiveness. Fewer will successfully address the entire patient experience.
The next wave of innovation will likely be defined not just by how much weight a drug can help patients lose but by how easily patients can take it, how quickly it works, and how well they can stay on it. In that context, tolerability is no longer a secondary consideration; it is becoming a central pillar of obesity drug development.
As the field continues to evolve, one thing is clear: the therapies that succeed will be those that patients can actually live with.
About The Author
